干扰素-α2b联合拉米夫定治疗慢性乙型肝炎的临床效果

Effect of Interferon-α2b Combined with Lamivudine on Clinical Efficacy of Chronic Hepatitis B

目的:探讨干扰素-α2b联合拉米夫定治疗慢性乙型肝炎的临床效果。方法:选取2017年9月-2019年7月笔者所在医院收治的慢性乙型肝炎患者104例,根据使用药物的不同分为两组,对照组52例,应用拉米夫定治疗,研究组52例,应用干扰素-α2b联合拉米夫定治疗。比较两组临床疗效、肝功能指标变化、血清HBsAg、肝细胞内tDNA、HBVcccDNA水平情况、不良反应。结果:研究组应答率高于对照组(P<0.05);研究组治疗后TBIL、AST、ALT低于对照组(P<0.05);研究组治疗后血清HBsAg、肝细胞内tDNA、HBVcccDNA水平均低于对照组(P<0.05);研究组白细胞计数下降、血小板计数下降、食欲下降发生率低于对照组(P<0.05)。结论:慢性乙型肝炎患者治疗过程中采用干扰素-α2b联合拉米夫定可提高临床效果,临床上应当进一步推广应用。

Objective:To investigate the effect of Interferon-α2b combined with Lamivudine on the clinical efficacy in patients with chronic hepatitis B.Method:A total of 104 patients with chronic hepatitis B in our hospital from September 2017 to July 2019 were selected and divided into two groups according to the different drugs used.The 52 patients in the control group were treated with Lamivudine,and the 52 patients in the study group were treated with Interferon-α2b combined with Lamivudine.The clinical efficacy,liver function index changes,serum HBsAg,intrahepatic tDNA,HBVcccDNA levels and adverse reactions were compared between the two groups.Result:The response rate of the study group was higher than that of the control group(P<0.05).TBIL,AST,ALT in the study group after treatment were lower than those in the control group(P<0.05).The levels of serum HBsAg,intrahepatic tDNA and HBV cccDNA in the study group after treatment were lower than those in the control group(P<0.05).The white blood cell count,platelet count and appetite decline probability of the study group were lower than those of the control group(P<0.05).Conclusion:Interferon-α2b combined with Lamivudine is effective in the treatment in patients with chronic hepatitis B,which can improve the clinical efficacy,it should be further popularized and applied in clinical.